About Us
DiaMedica Therapeutics is a clinical-stage biopharmaceutical company committed to changing the treatment paradigm for acute ischemic stroke (AIS) and cardio-renal disease. Our initial product candidate, DM199, mimics the behavior of naturally occurring human tissue kallikrein-1 (KLK1) proteins to increase collateral circulation in stroke-affected tissue and improve blood pressure control and overall kidney function.